UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 73

Sortiert nach

Updated meta-analysis of randomized controlled trials (RCTs) to determine the CDK 4/6 inhibitors associated venous thromboembolism (VTE) risk in hormone receptor-positive breast cancer (BC) patients

Annals of oncology, 2018-10, Vol.29, p.viii606-viii606

2018

Volltextzugriff (PDF)

Risk of health-related quality of life events and pulmonary toxicities in recurrent ovarian cancer patients treated with poly adenosine diphosphate ribose polymerase (PARP) inhibitors maintenance

Annals of oncology, 2018-10, Vol.29, p.viii627-viii628

2018

Volltextzugriff (PDF)

Risk of secondary hematological malignancies and hematological toxicities in recurrent ovarian cancer patients treated with poly adenosine diphosphate ribose polymerase (PARP) inhibitors maintenance

Annals of oncology, 2018-10, Vol.29, p.viii343-viii344

2018

Volltextzugriff (PDF)

Incidence of cardiac toxicities in patients with advanced non-small cell lung cancer treated with osimertinib: A combined analysis of two phase III randomized controlled trials

Annals of oncology, 2018-10, Vol.29, p.viii500-viii500

2018

Volltextzugriff (PDF)

A systematic review and meta- analysis of randomized controlled trials to evaluate the risk of gastrointestinal and hepatic toxicities in patients with recurrent ovarian cancer treated with poly adenosine diphosphate ribose polymerase inhibitors maintenance

Annals of oncology, 2018-10, Vol.29, p.viii346-viii346

2018

Volltextzugriff (PDF)

Acute Cardiac Toxicity Associated with High‐Dose Intravenous Methotrexate Therapy: Case Report and Review of the Literature

Pharmacotherapy, 2005-09, Vol.25 (9), p.1271-1276

2005

Volltextzugriff (PDF)

Reclaiming Liberalism

1st ed. 2019., 2020

Volltextzugriff (PDF)

P3.CR-03 Pulmonary Spindle Cell Neoplasm - Neoadjuvant Treatment and Response

Journal of thoracic oncology, 2018-10, Vol.13 (10), p.S1030-S1030

2018

Volltextzugriff (PDF)

Abstract P1-16-04: Risk of venous thromboembolism with abemaciclib based regimen versus other CDK 4/6 inhibitor containing regimens in patients with hormone receptor-positive HER2-negative metastatic breast cancer

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P1-P1-16-04

2019

Volltextzugriff (PDF)

P2.04-46 Tolerability and Treatment-Related Adverse Events of Upfront Pembrolizumab Combination Regimens in Advanced NSCLC Patients

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S726-S726

2019

Volltextzugriff (PDF)

Upfront atezolizumab chemoimmunotherapy-associated immune-related adverse events in patients with advanced non-small cell lung cancer

Annals of oncology, 2019-10, Vol.30, p.v618

2019

Volltextzugriff (PDF)

1296PTreatment-related adverse events and tolerability in patients with advanced renal cell carcinoma treated with first-line combination therapy with checkpoint inhibitors

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

Combination therapy with checkpoint inhibitors for first-line treatment of advanced renal cell carcinoma: A systematic review and meta-analysis of randomized controlled trials

Annals of oncology, 2019-10, Vol.30, p.v387-v388

2019

Volltextzugriff (PDF)

1513PAtezolizumab in combination with chemotherapy for first-line treatment of advanced non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials (RCTs)

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

958P - Combination therapy with checkpoint inhibitors for first-line treatment of advanced renal cell carcinoma: A systematic review and meta-analysis of randomized controlled trials

Annals of oncology, 2019-10, Vol.30, p.v387-v388

2019

Volltextzugriff (PDF)

1506P - Upfront atezolizumab chemoimmunotherapy-associated immune-related adverse events in patients with advanced non-small cell lung cancer

Annals of oncology, 2019-10, Vol.30, p.v618-v618

2019

Volltextzugriff (PDF)

1513P - Atezolizumab in combination with chemotherapy for first-line treatment of advanced non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials (RCTs)

Annals of oncology, 2019-10, Vol.30, p.v621-v621

2019

Volltextzugriff (PDF)

Atezolizumab in combination with chemotherapy for first-line treatment of advanced non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials (RCTs)

Annals of oncology, 2019-10, Vol.30, p.v621

2019

Volltextzugriff (PDF)

1296P - Treatment-related adverse events and tolerability in patients with advanced renal cell carcinoma treated with first-line combination therapy with checkpoint inhibitors

Annals of oncology, 2019-10, Vol.30, p.v527-v527

2019

Volltextzugriff (PDF)

1506PUpfront atezolizumab chemoimmunotherapy-associated immune-related adverse events in patients with advanced non-small cell lung cancer

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

Treatment-related adverse events and tolerability in patients with advanced renal cell carcinoma treated with first-line combination therapy with checkpoint inhibitors

Annals of oncology, 2019-10, Vol.30, p.v527

2019

Volltextzugriff (PDF)

958PCombination therapy with checkpoint inhibitors for first-line treatment of advanced renal cell carcinoma: A systematic review and meta-analysis of randomized controlled trials

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

P3.01-93 Osimertinib-Related Hematological and Pulmonary Toxicities in Advanced NSCLC Patients: Combined Analysis of Phase III Trials

Journal of thoracic oncology, 2018-10, Vol.13 (10), p.S902-S902

2018

Volltextzugriff (PDF)

P3.01-100 Risk of Gastrointestinal and Hepatic Toxicities in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Osimertinib

Journal of thoracic oncology, 2018-10, Vol.13 (10), p.S904-S904

2018

Volltextzugriff (PDF)

961PRisk of secondary hematological malignancies and hematological toxicities in recurrent ovarian cancer patients treated with poly adenosine diphosphate ribose polymerase (PARP) inhibitors maintenance

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

1 – 25 von 73

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(65)
Mit Volltextzugriff
(67)

Publikationsform

Sprache

Englisch
(73)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Science & Technology
(21)
Life Sciences & Biomedicine
(17)
Humans
(16)
Female
(6)
Biological And Medical Sciences
(5)
Medical Sciences
(5)
Pharmacology & Pharmacy
(5)
Chemistry, Medicinal
(4)
Adult
(3)
General & Internal Medicine
(3)
Male
(3)
Medicine, General & Internal
(3)
Oncology
(3)
Pharmacology. Drug Treatments
(3)
Structure-Activity Relationship
(3)
Adolescent
(2)
Antineoplastic Agents - Pharmacology
(2)
Antineoplastic Agents - Therapeutic Use
(2)
Asia
(2)
Binding Sites
(2)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Updated meta-analysis of randomized controlled trials (RCTs) to determine the CDK 4/6 inhibitors associated venous thromboembolism (VTE) risk in hormone receptor-positive breast cancer (BC) patients

Risk of health-related quality of life events and pulmonary toxicities in recurrent ovarian cancer patients treated with poly adenosine diphosphate ribose polymerase (PARP) inhibitors maintenance

Risk of secondary hematological malignancies and hematological toxicities in recurrent ovarian cancer patients treated with poly adenosine diphosphate ribose polymerase (PARP) inhibitors maintenance

Incidence of cardiac toxicities in patients with advanced non-small cell lung cancer treated with osimertinib: A combined analysis of two phase III randomized controlled trials

A systematic review and meta- analysis of randomized controlled trials to evaluate the risk of gastrointestinal and hepatic toxicities in patients with recurrent ovarian cancer treated with poly adenosine diphosphate ribose polymerase inhibitors maintenance

Acute Cardiac Toxicity Associated with High‐Dose Intravenous Methotrexate Therapy: Case Report and Review of the Literature

Reclaiming Liberalism

P3.CR-03 Pulmonary Spindle Cell Neoplasm - Neoadjuvant Treatment and Response

Abstract P1-16-04: Risk of venous thromboembolism with abemaciclib based regimen versus other CDK 4/6 inhibitor containing regimens in patients with hormone receptor-positive HER2-negative metastatic breast cancer

P2.04-46 Tolerability and Treatment-Related Adverse Events of Upfront Pembrolizumab Combination Regimens in Advanced NSCLC Patients

Upfront atezolizumab chemoimmunotherapy-associated immune-related adverse events in patients with advanced non-small cell lung cancer

1296PTreatment-related adverse events and tolerability in patients with advanced renal cell carcinoma treated with first-line combination therapy with checkpoint inhibitors

Combination therapy with checkpoint inhibitors for first-line treatment of advanced renal cell carcinoma: A systematic review and meta-analysis of randomized controlled trials

1513PAtezolizumab in combination with chemotherapy for first-line treatment of advanced non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials (RCTs)

958P - Combination therapy with checkpoint inhibitors for first-line treatment of advanced renal cell carcinoma: A systematic review and meta-analysis of randomized controlled trials

1506P - Upfront atezolizumab chemoimmunotherapy-associated immune-related adverse events in patients with advanced non-small cell lung cancer

1513P - Atezolizumab in combination with chemotherapy for first-line treatment of advanced non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials (RCTs)

Atezolizumab in combination with chemotherapy for first-line treatment of advanced non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials (RCTs)

1296P - Treatment-related adverse events and tolerability in patients with advanced renal cell carcinoma treated with first-line combination therapy with checkpoint inhibitors

1506PUpfront atezolizumab chemoimmunotherapy-associated immune-related adverse events in patients with advanced non-small cell lung cancer

Treatment-related adverse events and tolerability in patients with advanced renal cell carcinoma treated with first-line combination therapy with checkpoint inhibitors

958PCombination therapy with checkpoint inhibitors for first-line treatment of advanced renal cell carcinoma: A systematic review and meta-analysis of randomized controlled trials

P3.01-93 Osimertinib-Related Hematological and Pulmonary Toxicities in Advanced NSCLC Patients: Combined Analysis of Phase III Trials

P3.01-100 Risk of Gastrointestinal and Hepatic Toxicities in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Osimertinib

961PRisk of secondary hematological malignancies and hematological toxicities in recurrent ovarian cancer patients treated with poly adenosine diphosphate ribose polymerase (PARP) inhibitors maintenance

Suchergebnisse filtern